- •One third of pregnant women with heart disease used cardiac medication.
- •The use of cardiac medication was associated with adverse fetal events.
- •Birth weight was significantly lower in children of patients taking beta-blockers.
Methods and results
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to International Journal of Cardiology
- ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC).Eur Heart J. 2011; 32: 3147-3197
- Outcome of pregnancy in women with congenital heart disease: a literature review.J Am Coll Cardiol. 2007; 49: 2303-2311
- Patterns of outpatient antihypertensive medication use during pregnancy in a medicaid population.Hypertension. 2012; 60: 913-920
- Drugs in pregnancy.N Engl J Med. 1998; 338: 1128-1137
- Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.Hypertension. 2009; 54: 63-70
- Antihypertensive drugs in pregnancy.Semin Nephrol. 2011; 31: 70-85
- Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology.Eur Heart J. 2013; 34: 657-665
- Pregnancy and contraception in heart disease and pulmonary arterial hypertension.J Fam Plann Reprod Health Care. 2006; 32: 75-81
- Pregnancy outcomes in women with congenital heart disease.Circulation. 2006; 113: 517-524
- Predictors of pregnancy complications in women with congenital heart disease.Eur Heart J. 2010; 31: 2124-2132
- Prospective multicenter study of pregnancy outcomes in women with heart disease.Circulation. 2001 Jul 31; 104: 515-521
- Pregnancy and heart disease: time for a randomized controlled trial.Int J Cardiol. 2013; 9; 168: 3149-3151
- Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study.Lancet. 1998; 351: 311-316
- Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.Circulation. 2007; 115: 3015-3038
- Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.Hypertension. 2012; 60: 444-450
- Major congenital malformations after first-trimester exposure to ACE inhibitors.N Engl J Med. 2006; 354: 2443-2451
- Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.Pharmacoepidemiol Drug Saf. 2003; 12: 633-646
- Statin use during pregnancy: a systematic review and meta-analysis.Expert Rev Cardiovasc Ther. 2012; 10: 363-378
- Effect of maternal heart disease on fetal growth.Obstet Gynecol. 2011; 117: 886-891
- Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction.BJOG. 2014; 121: 618-626
- Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa.Arch Gynecol Obstet. 2012; 285: 1553-1562
- Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns.Birth Defects Res B Dev Reprod Toxicol. 2010; 89: 147-154
- Beta-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study.BMJ Open. 2012; 2
- Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society.J Clin Endocrinol Metab. 2007; 92: 804-810
- Neonatal and post-natal growth.Horm Res. 2000; 53: 42-49
- Weight in infancy and death from ischaemic heart disease.Lancet. 1989; 2: 577-580
- Size at birth as a predictor of mortality in adulthood: a follow-up of 350 000 person-years.Int J Epidemiol. 2005; 34: 655-663
- The thrifty phenotype hypothesis.Br Med Bull. 2001; 60: 5-20
- Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy.Eur J Heart Fail. 2010; 12: 767-778
☆Funding sources: The ROPAC is included in the EurObservational Research Programme (EORP) of the European Society of Cardiology. The EurObservational Research Programme (EORP) was sponsored by the following companies: Abbott Vascular Int., Amgen, Bayer Pharma, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific Int., Daiichi Sankyo Company, Menarini Int., Merck & Co., Inc. (MSD), Novartis, Pfizer, and Servier Int.
☆☆All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.